EE200100529A - Diabeedivastase agensi uudsed polümorfsed vormid:nende valmistamismeetod ja neid sisaldavad farmatseutilised kompositsioonid - Google Patents

Diabeedivastase agensi uudsed polümorfsed vormid:nende valmistamismeetod ja neid sisaldavad farmatseutilised kompositsioonid

Info

Publication number
EE200100529A
EE200100529A EEP200100529A EEP200100529A EE200100529A EE 200100529 A EE200100529 A EE 200100529A EE P200100529 A EEP200100529 A EE P200100529A EE P200100529 A EEP200100529 A EE P200100529A EE 200100529 A EE200100529 A EE 200100529A
Authority
EE
Estonia
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
polymorphic forms
antidiabetic agent
Prior art date
Application number
EEP200100529A
Other languages
English (en)
Estonian (et)
Inventor
Reddy Gaddam Om
Kumar Potlapally Rajender
Sirisilla Raju
Krishnamurthi Vyas
Rao Dharmaraja Sreenivasa
Sarma Mamillapalli Ramabhadra
Original Assignee
Dr. Reddy's Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB1999/000681 external-priority patent/WO2000063191A1/fr
Application filed by Dr. Reddy's Research Foundation filed Critical Dr. Reddy's Research Foundation
Publication of EE200100529A publication Critical patent/EE200100529A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/38—[b, e]-condensed with two six-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
EEP200100529A 1999-04-16 2000-04-17 Diabeedivastase agensi uudsed polümorfsed vormid:nende valmistamismeetod ja neid sisaldavad farmatseutilised kompositsioonid EE200100529A (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/IB1999/000681 WO2000063191A1 (fr) 1999-04-16 1999-04-16 Nouvelles formes polymorphes d'un agent antidiabetique: procede de preparation et composition pharmaceutique contenant ces dernieres
IN436MA1999 1999-04-19
PCT/IB2000/000470 WO2000063192A1 (fr) 1999-04-16 2000-04-17 Nouvelles formes polymorphes d'un agent antidiabetique, leur procede de preparation et compositions pharmaceutiques les renfermant

Publications (1)

Publication Number Publication Date
EE200100529A true EE200100529A (et) 2002-12-16

Family

ID=26318745

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100529A EE200100529A (et) 1999-04-16 2000-04-17 Diabeedivastase agensi uudsed polümorfsed vormid:nende valmistamismeetod ja neid sisaldavad farmatseutilised kompositsioonid

Country Status (17)

Country Link
EP (1) EP1171430A1 (fr)
CN (1) CN1351597A (fr)
AU (1) AU3831300A (fr)
BG (1) BG106022A (fr)
BR (1) BR0010683A (fr)
CA (1) CA2370401A1 (fr)
CZ (1) CZ20013711A3 (fr)
EE (1) EE200100529A (fr)
HR (1) HRP20010748A2 (fr)
HU (1) HUP0200758A3 (fr)
IL (1) IL145958A0 (fr)
MX (1) MXPA01010472A (fr)
NO (1) NO20015016L (fr)
PL (1) PL351492A1 (fr)
RU (1) RU2001130883A (fr)
TR (1) TR200103851T2 (fr)
WO (1) WO2000063192A1 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE309818T1 (de) 2000-03-08 2005-12-15 Novo Nordisk As Senkung des serum cholesterols
US6897199B2 (en) * 2001-02-05 2005-05-24 Dr. Reddy's Laboratories Ltd. Pharmaceutically acceptable salts of phenoxazine and phenothiazine compounds
EP2243776A1 (fr) 2001-10-12 2010-10-27 High Point Pharmaceuticals, LLC Piperidines substituées et leur utilisation dans le traitement de maladies liées au recepteur histaminique H3
IL162620A0 (en) 2001-12-21 2005-11-20 Novo Nordisk As Amide derivatives as gk activators
SI1505066T1 (sl) * 2002-04-19 2007-04-30 Faes Farma Sa Polimorf 4-(2-(4-(1-(2-etoksietil)-1h-benzimidazol-2-il) -1-piperidinil)-alfa, alfa-dimetil-benzenocetne kisline
EP2471533A1 (fr) 2002-06-27 2012-07-04 Novo Nordisk A/S Dérivés d'aryle carbonyle en tant qu'agents thérapeutiques
JP2007503453A (ja) 2003-05-14 2007-02-22 ノボ　ノルディスク　アクティーゼルスカブ 肥満症を治療するための新規化合物
BRPI0414890A (pt) 2003-09-30 2006-12-12 Novo Nordisk As composto, métodos de retardar a progressão de igt para diabete tipo 2, e de diabete tipo 2 para diabete que requer insulina, de tratar a obesidade ou prevenir o excesso de peso, de regular o apetite, de induzir saciedade, de impedir o ganho de peso, de aumentar o gasto de energia, e de tratar uma doença ou estado, composição farmacêutica, e, uso de um composto
EP1694356B1 (fr) 2003-12-09 2011-02-16 Novo Nordisk A/S Regulation d'une preference alimentaire au moyen d'agonistes de glp-1
PL1723128T3 (pl) 2004-01-06 2013-04-30 Novo Nordisk As Pochodne heteroarylowe mocznika oraz ich zastosowanie jako aktywatory glukokinazy
US20080113944A1 (en) 2004-05-04 2008-05-15 Novo Nordisk A/S Novel Indole Derivatives
WO2005120492A1 (fr) 2004-06-11 2005-12-22 Novo Nordisk A/S Remede contre l'obesite induite par les medicaments au moyen d'agonistes glp-1
CN101060856B (zh) 2004-11-22 2011-01-19 诺和诺德公司 可溶、稳定的含胰岛素制剂
MX2007006420A (es) 2004-12-03 2007-07-19 Novo Nordisk As Activadores heteroaromaticos de glucocinasa.
BRPI0613564A2 (pt) 2005-07-04 2011-01-18 Novo Nordisk As compostos, seus usos na preparação de composições farmacêuticas e composições farmacêuticas compreendendo os mesmos
BRPI0612996A2 (pt) 2005-07-14 2010-12-14 Novo Nordisk As ativadores de urÉia glucocinase
EP1910317B1 (fr) 2005-07-20 2013-07-03 Eli Lilly And Company Composés joints en position 1-amino
SI1951658T1 (sl) 2005-11-17 2012-11-30 Lilly Co Eli Antagonisti glukagonskega receptorja priprava interapevtska uporaba
SG170785A1 (en) 2006-03-28 2011-05-30 Transtech Pharma Benzothiazoles having histamine h3 receptor activity
AU2007267197B2 (en) 2006-05-29 2011-12-01 High Point Pharmaceuticals, Llc 3- (1, 3-Benzodioxol-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine H3 receptor antagonist
EP2097388B1 (fr) 2006-11-15 2011-09-07 High Point Pharmaceuticals, LLC Nouveaux 2-(2-hydroxyphényl)benzimidazoles utilisés pour traiter l'obésité et le diabète
EP2086951B1 (fr) 2006-11-15 2011-12-21 High Point Pharmaceuticals, LLC Nouvelles 2-(2-hydroxyphényl) benzothiadiazines utilisées pour traiter l'obésité et le diabète
EP2099777B1 (fr) 2007-01-11 2015-08-12 Novo Nordisk A/S Activateurs de l'urée glucokinase
JP2010013472A (ja) * 2009-09-09 2010-01-21 Faes Farma Sa ４−［２−［１−（２−エトキシエチル）−１Ｈ−ベンズイミダゾール−２−イル］−１−ピペリジニル］エチル］−α，α−ジメチルベンゼノ酢酸の多形体
BR112012021231A2 (pt) 2010-02-26 2015-09-08 Basf Plant Science Co Gmbh método para acentuar o rendimento em plantas, planta, construto, uso de um construto, método para a produção de uma planta transgênica, partes coletáveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco e método para a produção de um produto
EP2539364A1 (fr) 2010-02-26 2013-01-02 Novo Nordisk A/S Peptides de traitement de l'obésité
CA2792663A1 (fr) 2010-03-26 2011-09-29 Novo Nordisk A/S Nouveaux analogues du glucagon
WO2012104834A1 (fr) 2011-02-03 2012-08-09 Pharmedica Ltd. Nouveaux films à dissolution orale pour administration d'insuline, pour traitement du diabète
CA2830974A1 (fr) 2011-03-28 2012-10-04 Jesper F. Lau Nouveaux analogues de glucagon
AR088161A1 (es) 2011-09-23 2014-05-14 Novo Nordisk As Analogos de glucagon
WO2013082106A1 (fr) 2011-12-02 2013-06-06 The General Hospital Corporation Différenciation en adipocytes bruns
CN105307672B (zh) 2013-04-18 2021-01-05 诺和诺德股份有限公司 用于医学用途的稳定、延长的glp-1/胰高血糖素受体共激动剂
JP2017525656A (ja) 2014-06-04 2017-09-07 ノヴォ ノルディスク アー／エス 医療用のｇｌｐ−１／グルカゴン受容体コアゴニスト
MA49883A (fr) 2017-03-15 2021-04-21 Novo Nordisk As Composés bicycliques aptes à se lier au récepteur de mélanocortine 4
WO2019219714A1 (fr) 2018-05-15 2019-11-21 Novo Nordisk A/S Composés capables de se lier au récepteur de la mélanocortine 4
WO2020053414A1 (fr) 2018-09-14 2020-03-19 Novo Nordisk A/S Composés bicycliques aptes à se lier aux agonistes du récepteur de la mélanocortine 4

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089514A (en) * 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
US5248699A (en) * 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
IN182496B (fr) * 1996-02-20 1999-04-17 Reddy Research Foundation
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
FR2746099B1 (fr) * 1996-03-13 1998-04-30 Procede ameliore pour la preparation de derives de l'acide 3-(10-phenothiazyl)-propanoique ou 3-(10-phenoxazyl)-propanoique
EP0844997A1 (fr) * 1996-06-19 1998-06-03 Dr. Reddy's Research Foundation Nouvelles formes polymorphes de la troglitazone ayant une activite anti-diabetique augmentee et procede pour leur preparation
WO1999019313A1 (fr) * 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Nouveaux composes tricycliques et leur utilisation en medecine, procede de preparation de ces derniers et compositions pharmaceutiques les contenant
WO1999020614A1 (fr) * 1998-05-27 1999-04-29 Dr. Reddy's Research Foundation Composes bicycliques, procede de preparation et compositions pharmaceutiques les contenant
AU1887999A (en) * 1998-01-29 1999-08-16 Dr. Reddy's Research Foundation Novel alkanoic acids and their use in medicine, process for their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
CA2370401A1 (fr) 2000-10-26
NO20015016L (no) 2001-12-11
EP1171430A1 (fr) 2002-01-16
TR200103851T2 (tr) 2002-04-22
HRP20010748A2 (en) 2003-02-28
MXPA01010472A (es) 2002-05-06
BG106022A (bg) 2002-04-30
BR0010683A (pt) 2003-07-01
PL351492A1 (en) 2003-04-22
HUP0200758A3 (en) 2003-07-28
CZ20013711A3 (cs) 2002-07-17
RU2001130883A (ru) 2004-03-20
IL145958A0 (en) 2002-07-25
HUP0200758A2 (hu) 2002-07-29
CN1351597A (zh) 2002-05-29
NO20015016D0 (no) 2001-10-15
AU3831300A (en) 2000-11-02
WO2000063192A1 (fr) 2000-10-26

Similar Documents

Publication Publication Date Title
EE200100529A (et) Diabeedivastase agensi uudsed polümorfsed vormid:nende valmistamismeetod ja neid sisaldavad farmatseutilised kompositsioonid
EE04673B1 (et) Kinoliini derivaadid, nende valmistamine ja kasutamine ravimina ning neid sisaldavad farmatseutilised kompositsioonid
EE04799B1 (et) Ühendid, mis on kasulikud põletikuvastaste vahenditena, nende ühendite valmistamise meetodid ja neid sisaldavad farmatseutilised kompositsioonid
EE200000791A (et) Uudsed atsüülpseudopeptiidid, nende valmistamise meetod ja neid sisaldavad farmatseutilised kompositsioonid
EE200200149A (et) Kinasoliinühendid ja neid sisaldavad ravimkoostised
EE200100484A (et) Bitsüklilised heterotsüklilised ühendid, neid ühendeid sisaldavad farmatseutilised kompositsioonid,ja nende valmistamise meetodid
EE04276B1 (et) Kinoliini derivaadid, nende valmistamine ja kasutamine ravimina ning neid sisaldavad farmatseutilised kompositsioonid
EE200000168A (et) Karboksamidotiasoolderivaadid, nende valmistamine ja neid sisaldavad farmatseutilised kompositsioonid
EE200200138A (et) Kinolüülpropüülpiperidiini derivaadid, nende valmistamine ja neid sisaldavad kompositsioonid
EE200000707A (et) Oksasolidinooni derivaadid, nende valmistamismeetod ja neid sisaldavad farmatseutilised kompositsioonid
EE200300046A (et) Asabitsüklilised ühendid, nende valmistamine ja kasutamine ravimitena ning neid sisaldav farmatseutiline kompositsioon
EE04613B1 (et) Sahhariidijääkidega asendatud 1,4-bensotiasepiin-1,1-dioksiidi derivaadid, meetod nende valmistamiseks, ühendite kasutamine ning neid sisaldav ravim
EE200200065A (et) 3-aminopürasooli derivaadid, nende valmistamine ja kasutamine vähivastaste toimeainetena ning neid sisaldav farmatseutiline kompositsioon
EE200300080A (et) Polüarüülkarboksamiidühendid, nende valmistamine ja kasutamine lipiiditaset alandavate toimeainetena ning neid sisaldav farmatseutiline kompositsioon
PT1066027E (pt) Composicao farmaceutica de topiramato
EE04015B1 (et) Asendatud 2,4-tiasolidiindiooni derivaadid, nendevalmistamismeetodid ja neid sisaldavad farmatseutilised kompositsioonid
EE04717B1 (et) Indolüülpiperidiinühendid, nende valmistamismeetod, kompositsioon ja nende kasutamine
EE200300234A (et) Bifenüülkarboksamiidühendite kasutamine lipiiditaset alandavate toimeainetena, meetod nende valmistamiseks ning neid sisaldav farmatseutiline kompositsioon
EE200200105A (et) Radiofarmatseutilised saadused ja nende valmistamise meetod
HUP0201543A2 (en) Use of substituted imidazothiazoles as antidepressant agents, pharmaceutical compositions containing them and their preparation
EE05004B1 (et) Aminotiasooli derivaadid, nende valmistamine ja neid sisaldavad farmatseutilised kompositsioonid
EE03395B1 (et) Bensotiasolooni derivaadid, protsessid ja kasutatud vaheühendid nende saamiseks ning neid sisaldavad ravimkoostised
EE200000421A1 (et) Uued pentasahhariidid, nende valmistamismeetodid ja neid sisaldavad farmatseutilised kompositsioonid
EE200100173A (et) 2-fenüülpüraan-4-ooni derivaadid, nende valmistamismeetod ja kasutamine, vaheühendite kasutamine jafarmatseutiline kompositsioon
EE05192B1 (et) Trptamiini derivaadid ja analoogsed hendid ning neid sisaldavad farmatseutilised preparaadid